Celldex Therapeutics reported $51.47M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Agenus USD 249.24M 74.25M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Celldex Therapeutics USD 51.47M 481K Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Northwest Biotherapeutics USD 87.9M 3.98M Sep/2025
Pfizer USD 34.35B 2.64B Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Roche Holding CHF 28B 421M Dec/2025